Coronavirus (COVID-19)
COVID-19 Vaccine Breakthrough Cases: Data from the States
This Policy Watch reviews the websites and other official state sources for all 50 states and D.C. to see which are providing data on COVID-19 breakthrough cases, hospitalizations and deaths, how regularly, and what those data may tell us.
Greater Than COVID
A New Campaign with Health Care Workers to Reach Latinos in U.S. about the COVID-19 Vaccines
THE CONVERSATION / LA CONVERSACIÓN expands to address information needs about the COVID-19 vaccines in the Latinx community with new videos featuring doctors, nurses and promotoras (community health workers) in English and Spanish. Produced by KFF (Kaiser Family Foundation) under its Greater Than COVID public information response, the campaign is presented with UnidosUS. Previous messaging featured Black health care workers. YouTube/Google, Facebook, Twitter and Pinterest are supporting distribution.
Read More
State Data and Policy Actions to Address Coronavirus
There have been over 3 million cases and 131,000 deaths due to COVID-19 in the U.S. Every state and Washington D.C. have eased or lifted at least one social distancing requirement — including 39 states that have eased or lifted stay-at-home orders.
COVID-19 Coronavirus Tracker
This tracker provides the number of cases and deaths from novel coronavirus by country, the trend in case and death counts by country, and a global map of showing which countries have cases and deaths. There have been over 11.8 million confirmed cases and 544,000 confirmed deaths worldwide.
COVID-19 and Related State Data
Use this tool to create custom reports of COVID-19 and related state data. Group COVID-19 cases and deaths with indicators like total hospital beds, health insurance coverage and unemployment claims.
-
Most of the Public Says the U.S. Should Play a Major Role in Distributing COVID-19 Vaccines Globally
With supply having increased significantly and eligibility fully open to adults in all states as of April 19, this analysis estimates that COVID-19 vaccine supply will exceed demand across the U.S. over the next 2 to 4 weeks.
-
Global COVID-19 Vaccine Equity: U.S. Policy Options and Actions to Date
This brief examines U.S. policy options for helping expand global access to COVID-19 vaccines, focusing on four main areas: in-kind donations of vaccine doses, additional funding for global access mechanisms like COVAX, helping expand global vaccine manufacturing, and relaxing or waiving intellectual property protections on vaccine technologies. We summarize what the administration has done to date in these areas and policy issues related to each.
-
The Next Stage of COVID-19 Vaccine Roll-Out in United States: Children Under 12
Analysis of characteristics of children under 12 in the U.S. to help inform COVID-19 vaccination efforts when they become eligible.
-
Key Questions About COVID-19 Vaccine Mandates
This brief explains the legal basis for vaccine mandates by the federal government, states, and private employers; highlights considerations for mandates while the COVID-19 vaccine is under an EUA; and discusses mandate exemptions based on disability or religious objection.
Key Questions: HIV and COVID-19
This brief examines and summarizes what we know about COVID-19 and HIV including, what we know about COVID-19 risk, disease severity, vaccination, and federal response. It also explores how people with HIV are overly represented in many of the demographic groups hardest hit by the pandemic.
Are Health Centers Facilitating Equitable Access to COVID-19 Vaccinations?
The latest data show that people of color made up 64 percent of people receiving the first dose and 61 percent of people receiving the second/final dose of the COVID-19 vaccine at community health centers.COVID-19 Vaccination among American Indian and Alaska Native People
This brief presents available data on COVID-19 vaccinations among AIAN people from federal and state sources and discusses factors contributing to success in these vaccination efforts.
At-Home SARS-CoV-2 Testing: What Are the Options?
This interactive table includes vendors selling at-home SARS-CoV-2 diagnostic tests that have received emergency use authorization (EUA) from the Food and Drug Administration (FDA).
Five Things to Know about the Cost of COVID-19 Testing and Treatment
This brief answer key questions on affordability of COVID-19 testing and treatment for people who are uninsured and those insured through private coverage, Medicare, and Medicaid.
FAQs on Medicare Coverage and Costs Related to COVID-19 Testing and Treatment
These FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries.
COVID-19 Test Prices and Payment Policy
This analysis examines list prices for COVID-19 testing at the largest hospitals in every state and finds they range widely from $20 to $850. Federal law now requires private insurers to cover COVID-19 tests at no cost to the patient and provides funding for people without health insurance.